Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

GSK exec stresses need to move away from 'fragmented' approach to drug delivery

Talking of breaking internal siloes has become a corporate-speak cliche. But in a speech that could be described as brutally honest, GlaxoSmithKlines' head of drug delivery nevertheless brought the importance of doing so to life during last week's Partnership Opportunities in Drug Delivery conference.

Top 10 Phase III disasters of 2014

Welcome to the hall of shame, where blockbuster drug projections go to die. This list includes some drugs that clearly should never have wound up in Phase III to begin with, a few that were steered back to the clinic in a doomed attempt to mine something positive, and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology.

Adaptimmune's novel cancer treatment posts promising early results

Adaptimmune's pioneering approach to cancer immunotherapy has charted some impressive results in a small study. And while the biotech is quick to point out that it's early days yet, the data underscore the potential of a therapy that has convinced GlaxoSmithKline to bet up to $350 million on its future.

NewLink Ebola vaccine trial begins in U.S. while Glaxo takes its jab to Mali

The race is on to test an experimental Ebola vaccine as West Africa grapples with an out-of-control outbreak and the U.S. scrambles to rectify breaches in protocol after a patient with the virus died at a Dallas hospital and a healthcare worker tested positive for the infection.

GlaxoSmithKline chops up mature drugs portfolio for $3B sale

GlaxoSmithKline may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products.

GSK starts unloading older meds by region, with $3B portfolio up for grabs

In its latest move to revive profits and slim down a sagging portfolio, GlaxoSmithKline is planning to put $3 billion worth of older drugs on the chopping block, shedding products by geographical region.

Novartis, GSK shake up executive ranks as overhaul continues

Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.

Report: Financial conflicts sway studies of flu fighters Tamiflu and Relenza

A debate has raged over the past couple of years over whether world governments are wasting money by stockpiling Roche's Tamiflu and GlaxoSmithKline's Relenza to help combat a potential flu epidemic. At issue is a tough question: Are the drugs effective enough to justify the estimated $2 billion spent to stockpile them?

GSK may give Ebola vaccine to West African healthcare workers in early 2015

As the Ebola outbreak continues to ravage Liberia, Guinea and Sierra Leone, GlaxoSmithKline said Phase I trials of its experimental Ebola vaccine are expected to start in West Africa in the next few weeks, and Phase II trials are likely to begin in early 2015.

GE, GSK partner to develop genetic oncology testing service

GlaxoSmithKline has disclosed its second deal in less than a week designed to improve the analysis of genetic mutations in oncology. The latest collaboration is with  GE Healthcare  to establish a network of clinical laboratories to identify genetic mutations associated with specific tumor types.